Compare NTIC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | ATYR |
|---|---|---|
| Founded | 1970 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.9M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | NTIC | ATYR |
|---|---|---|
| Price | $7.57 | $0.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 34.7K | ★ 2.0M |
| Earning Date | 01-09-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $84,234,474.00 | $190,000.00 |
| Revenue This Year | $7.89 | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | $4,073.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.75 | $0.64 |
| 52 Week High | $14.20 | $7.29 |
| Indicator | NTIC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 42.35 |
| Support Level | $7.50 | $0.69 |
| Resistance Level | $7.98 | $0.76 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 36.51 | 29.49 |
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.